menu
    • menu

    Company profile for Abbott Laboratories

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We understand that the first step to living your best life is good health. Everything we make is designed to help you do just that. That’s our commitment to building life-changing technologies that keep your heart healthy, nourish your body at every stage of life, help you feel and move better, and bring you information, medicines and breakthroughs to manage your health.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Abbott LaboratoriesUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    100 Abbott Park Road, Abbott Park, IL 60064 - (224) 667-6100
    Telephone
    Telephone
    +91-22-3816 2000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.abbott.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/abbott-/
    youtube
    YouTube
    Twitter
    Twitter
    https://twitter.com/AbbottNews

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    CPhI India 2024

    CPhI India 2024

    Not Confirmed

    envelop Contact Supplier

    CPhI India 2024

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “LGM Pharma has made significant strides in meeting the evolving needs of its clients”

    “LGM Pharma has made significant strides in meeting the evolving needs of its clients”

    This week, SpeakPharma interviews four senior executives of LGM Pharma — Shailesh Vengurlekar (Senior VP, Quality and Regulatory Affairs), Deepak Thassu (Senior VP, R&D and Regulatory Submission), Selwyn Lustman (Senior VP, Global Sourcing and Procurement), and Mike Stenberg (VP, Business Development). The four VPs talk about expansion in manufacturing capabilities of the Florida-based contract development and manufacturing organization (CDMO), expertise that makes LGM a strong partner and the criteria it adopts while selecting its suppliers.  HIGHLIGHTS// expansion in manufacturing capabilities/ expertise that makes LGM a strong partner/ criteria for selecting its suppliers LGM Pharma recently invested heavily in expanding its CDMO capabilities by 50 percent. Can you share why offering standalone analytical testing services is important to LGM Pharma’s growth strategy? How does it benefit your clients? Vengurlekar: This recent expansion in CDMO capabilities is part of LGM Pharma’s growth strategy that lays importance on diversification. One key area of this diversification is the offering of standalone Analytical Testing Services (ATS). This service plays a crucial role in supporting our clients by providing them with greater flexibility and reliability. LGM Pharma is already a well-established leader in the API supply chain. We have now identified a significant need in the market and are now serving compounding pharmacies, including 503A and 503B facilities. These pharmacies not only require high-quality, GMP-compliant APIs, but also need a trusted, compliant, and capable laboratory to analyze both their APIs and compounded products. Recognizing this opportunity to further support our clients, LGM Pharma has expanded into ATS. We have witnessed tremendous growth since we’ve launched these services. By offering ATS under a separate legal entity — LGM Pharma Solutions — we are able to provide an additional layer of flexibility to our clients. This structure eliminates any conflict of interest. While LGM Pharma LLC handles API supply, LGM Pharma Solutions focuses on delivering top-tier ATS, all under the same LGM Pharma umbrella. This setup enhances trust and allows our clients to work with us more seamlessly. HIGHLIGHTS// diversified into standalone ATS/ well-established leader in API supply chain/ serving compounding pharmacies/ offering APIs and ATS under different legal entities. While suppositories offer clear advantages for certain medications, can you describe how LGM Pharma plans to leverage its expertise in this area to address specific unmet needs in the growing women’s health market? Thassu: We’re taking a dual approach to enhance both our R&D and manufacturing capabilities. First, we’ve introduced a new semi-automatic machine that allows us to produce smaller batches more efficiently. This is particularly important for the suppository segment, where demand doesn’t require large-scale production. The new system enables quicker adjustments to the manufacturing process, providing us with greater flexibility of producing small batches. Second, many of the materials we handle in the women’s health sector are sensitive to heat, light, and oxygen. To address this, we’re upgrading our facility to accommodate these specialized requirements. This ensures we can develop and manufacture products while maintaining the integrity of heat-, light-, and oxygen-sensitive ingredients. Additionally, we’re working closely with clients to prepare for various technical challenges. Whether it’s processing homeopathic ingredients or handling delicate fermentation-based materials, which are highly sensitive to both light and heat, our team has upgraded its skills and equipment to manage these complexities. From technology advancements in manufacturing to specialized handling conditions and improved technical expertise, we’ve made significant strides to ensure we can meet the evolving needs of our clients and their products. HIGHLIGHTS// dual approach to enhance R&D and manufacturing capabilities/ upgrading facilities to accommodate specialized requirements/ working with clients to address challenges. The pandemic underscored supply chain problems. Can you detail the specific criteria LGM Pharma uses while selecting suppliers for its manufacturing processes? Lustman: LGM looks at many facets of a manufacturer before proceeding to approve them for a specific project. We start by checking their regulatory history with the US Food and Drug Administration (FDA) and other authorities. We try to find out if they have received any warning letters. What is their inspection history? Have they received NAIs (no action indicated) and VAIs (voluntary action indicated)? We further investigate the company’s overall business status — we need to know that they are a stable partner to work with in the long term. Manufacturers are then assessed for their overall technology and the number of employees working in various fields, such as R&D, quality control, quality assurance, regulatory affairs, manufacturing, and the educational levels of these employees. Once we have established that the manufacturer is a potential partner, we check their status for a particular project. We look at their advantages, and whether they have a non-infringing route of synthesis (ROS) that will allow early launch. Are they developing a second process that will be more competitive in pricing? And, does the manufacturer have the necessary capacity and/or spare capacity for the project that we are assessing? We need to know whether the drug master file (DMF) has been registered, the current batch size, and the potential for increase in batch size. Pricing is a key indicator — we need to know whether the pricing of the manufacturer is competitive or not, and if the manufacturer will be able to compete in the future as the project matures. LGM always assesses for quality, price, and delivery. Goods must be of the correct quality, at the right price, with delivery time as desired, in order to meet commercial needs. HIGHLIGHTS// investigate various facets of manufacturer before approving them for a project/ look at advantages, non-infringing ROS/ assess for quality, price, delivery Can you highlight specific capabilities and experiences LGM Pharma possesses that make it a strong partner for companies developing antibody-drug-conjugates (ADCs)? Stenberg: ADCs are often peptides linked with small molecules. However, they may also be peptides linked with oligonucleotides. Regardless, LGM can help manage the supply chain associated with the components that are used in the conjugation of the ADC. LGM has extensive experience, and an extensive network around sourcing and managing the supply chain associated with ADC components. LGM’s experience and capabilities extend to sourcing peptides, small molecules or oligonucleotides used in the conjugation process. Additionally, given our deep relationships in the supply chain aspect of this process, LGM may also be able to identify partners who can help with the conjugation process itself. HIGHLIGHTS// extensive experience, network around sourcing, managing supply chain associated with ADC components / identify partners that can help with conjugation process

    Impressions: 466

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/lgm-pharma-has-made-significant-strides-in-meeting-the-evolving-needs-of-its-clients

    #SpeakPharma With LGM Pharma
    09 Nov 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Medical Breakthroughs in 2024: Alzheimer’s, schizophrenia, COPD, MASH see pathbreaking treatments

    Medical Breakthroughs in 2024: Alzheimer’s, schizophrenia, COPD, MASH see pathbreaking treatments

    This year has seen pivotal advancements in medical innovation. The US Food and Drug Administration (FDA) has approved several groundbreaking therapies that promise to transform patient care across multiple therapeutic areas.Some of the therapies approved have revolutionary delivery mechanisms, while others are first-in-class treatments for previously unaddressed conditions. This week, PharmaCompass brings you a compilation of new pathbreaking approvals of 2024, including advancements in neurology, chronic conditions, mental health conditions, and innovative solutions for various other ailments.Lilly, Alpha Cognition, BMS transform neurological care with new Alzheimer’s, schizophrenia drugsThe neurological treatment landscape saw several major breakthroughs in 2024, particularly in the treatment of Alzheimer’s disease (AD). Eli Lilly’s Kisunla represents a significant advancement in treating early, symptomatic AD. Following decades of failed efforts, Kisunla’s approval, along with that of Eisai-Biogen’s Leqembi last year, marks a turning point in addressing AD.The drug works by targeting and clearing beta amyloid plaque from the brain, thereby attacking the disease’s underlying pathology, rather than just managing symptoms. Administered as an infusion every four weeks, Kisunla’s Medicare coverage makes it accessible to patients in the US who desperately need new treatment options. Alpha Cognition’s Zunveyl emerged as a promising new oral treatment for mild-to-moderate Alzheimer’s-related dementia. Only the second oral AD treatment approved by the FDA in over a decade, Zunveyl is a prodrug, or a biologically inactive compound that can be metabolized by the body to produce a drug. It remains inactive as it passes through the stomach and enhances cholinergic function in the brain.Perhaps one of the most exciting breakthroughs of 2024 was Bristol-Myers Squibb’s Cobenfy. This revolutionary antipsychotic medication for schizophrenia represents the first novel approach to treatment since the 1950s. Unlike traditional antipsychotics that target dopamine receptors, Cobenfy works through cholinergic receptors, offering new hope to patients who struggle with the side effects of conventional treatments.Traditional antipsychotics have been associated with several mild and serious side effects such as weight gain, feeling unmotivated and sluggish, high rates of cardiac disease, and even early death. Cobenfy’s innovative mechanism of action has generated excitement in the medical community. Experts project Cobenfy to bring in US$ 7.5 billion in peak annual sales, thereby validating BMS’ recent, US$ 14-billion acquisition of Karuna Therapeutics.Verona, Sanofi’s drugs revolutionize COPD care; Madrigal’s Rezdiffra offers hope to MASH patients The landscape of chronic obstructive pulmonary disease (COPD) treatment saw remarkable advances in 2024. Verona Pharma’s Ohtuvayre brings the first new mechanism of action in over two decades for COPD treatment. This dual-action, inhaled medication serves as both a bronchodilator and an anti-inflammatory agent, offering a comprehensive approach to symptom management.Adding to this progress, Sanofi and Regeneron’s Dupixent achieved a historic milestone by becoming the first biologic approved for treating COPD. Dupixent is Sanofi’s best-selling drug. It is poised to cross over € 21 billion (US$ 23.5 billion) in sales by 2030, with COPD likely to contribute US$ 2.9 billion, predict analysts. Over 390 million people are living with COPD worldwide.In the field of liver disease, Madrigal Pharmaceuticals’ Rezdiffra became the first FDA-approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver scarring. This approval represents a breakthrough in a field that has been notorious for being a graveyard for failed programs. Rezdiffra offers hope to patients with this common liver condition, which primarily affects those with obesity or type 2 diabetes. The American Liver Foundation has termed this approval a “game-changing” moment in hepatology.For the rare disease community, Ipsen’s Iqirvo emerged as the first new medicine approved in nearly a decade for primary biliary cholangitis (PBC). This first-in-class peroxisome proliferator-activated receptor (PPAR) agonist offers new hope for the approximately 100,000 Americans affected by this condition, particularly women aged 30 to 60 years.A significant breakthrough for patients with hypoparathyroidism came with the approval of Ascendis’ Yorvipath, making it the only treatment for hypoparathyroidism in adults. By directly addressing the underlying hormone deficiency, Yorvipath helps stabilize calcium levels in the blood, reducing the treatment burden associated with managing symptoms through calcium and vitamin D supplements alone.In the realm of pulmonary medicine, Merck’s Winrevair emerged as the first new therapy for pulmonary arterial hypertension (PAH) in over a decade. As the first approved activin-signaling inhibitor therapy, Winrevair represents a novel approach to treating this rare but severe condition that doctors call a “ticking time bomb”. The drug is the first treatment that targets the underlying cause of the lung condition, which typically leads to death within a decade of diagnosis.ARS Pharma launches nasal spray alternative to EpiPen, Eicos introduces med for severe frostbiteLeading the charge in innovative drug delivery is ARS Pharma’s Neffy, the first-ever nasal spray alternative to the EpiPen for treating severe allergic reactions. This groundbreaking advancement represents the first major innovation in anaphylaxis treatment in over a decade. For children and individuals with needle phobia, this nasal spray format addresses one of the most significant barriers to timely treatment of allergic emergencies. Speaking of emergency medicine, Eicos Sciences’ Aurlumyn made history as the first FDA-approved treatment for severe frostbite. This approval fills a critical gap in emergency care, offering a medical intervention that could prevent the need for amputation in severe cases.The cardiovascular space saw its first oral anti-hypertensive therapy that works through a new therapeutic pathway in almost 40 years. Idorsia’s Tryvio is a treatment for hypertension that offers new hope to patients whose blood pressure remains inadequately controlled on existing medications. Idorsia expects millions of patients to benefit from it.Our view This year, the pharmaceutical industry has taken a remarkable leap forward by addressing some of healthcare’s most challenging conditions. Treatments like BMS’ Cobenfy for schizophrenia and Madrigal’s Rezdiffra for MASH demonstrate the industry’s growing ability to translate science into practical therapies. With the growing use of artificial intelligence in the drug industry, we hope that these approvals are just a precursor to a bevy of pathbreaking therapies in the years to come. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 610

    https://www.pharmacompass.com/radio-compass-blog/medical-breakthroughs-in-2024-alzheimer-s-schizophrenia-copd-mash-see-pathbreaking-treatments

    #Phispers by PHARMACOMPASS
    14 Nov 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Abbott India reports Q2 FY25 st&alone PAT at Rs. 358.61 Cr
    Abbott India reports Q2 FY25 st&alone PAT at Rs. 358.61 Cr

    08 Nov 2024

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/abbott-india-reports-q2-fy25-standalone-pat-at-rs-35861-cr-16408

    INDPHARMAPOST
    08 Nov 2024
    Share Share
    Diamyd® Treatment Data to Be Shared at 2024 IDS Diabetes Congress
    Diamyd® Treatment Data to Be Shared at 2024 IDS Diabetes Congress

    06 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/in-depth-analysis-showing-robust-diamyd-treatment-effects-across-clinical-trials-to-be-shared-at-the-2024-ids-diabetes-congress-302297338.html

    PR NEWSWIRE
    06 Nov 2024
    Share Share
    Abbott posts positive, longer-term data for its Esprit BTK stent
    Abbott posts positive, longer-term data for its Esprit BTK stent

    05 Nov 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/medtech/abbott-posts-positive-longer-term-data-its-dissolving-esprit-btk-stent

    FIERCE BIOTECH
    05 Nov 2024
    Share Share
    Abbott, Reckitt cleared of liability in latest preterm formula case
    Abbott, Reckitt cleared of liability in latest preterm formula case

    02 Nov 2024

    // REUTERS

    https://www.reuters.com/legal/abbott-reckitt-cleared-liability-latest-preterm-formula-case-2024-10-31/

    REUTERS
    02 Nov 2024
    Share Share
    Abbott share rise after 1st win in premature infant formula trial
    Abbott share rise after 1st win in premature infant formula trial

    01 Nov 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/abbott-shares-rise-after-securing-first-win-premature-infant-formula-trial-2024-11-01/

    REUTERS
    01 Nov 2024
    Share Share
    TCT: Abbott atherectomy study fails vs. balloon angioplast
    TCT: Abbott atherectomy study fails vs. balloon angioplast

    29 Oct 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/medtech/tct-2024-abbotts-coronary-atherectomy-study-fails-outperform-conventional-balloon

    FIERCE BIOTECH
    29 Oct 2024
    Share Share

    USDMF

    read-more
    read-more

    01

    9-(s)-erythromycylamine

    U.S.A
    Compamed
    Not Confirmed
    arrow

    02

    Amikacin Sulfate

    U.S.A
    Compamed
    Not Confirmed
    arrow

    03

    Amrinone

    U.S.A
    Compamed
    Not Confirmed
    arrow

    04

    Arbutamine

    U.S.A
    Compamed
    Not Confirmed
    arrow

    05

    Arsanilic Acid (sodium Arsanilate)

    U.S.A
    Compamed
    Not Confirmed
    arrow

    06

    Arsanilic Acid--sodium Arsanilate Wi...

    U.S.A
    Compamed
    Not Confirmed
    arrow

    07

    Atracurium Besylate

    U.S.A
    Compamed
    Not Confirmed
    arrow

    08

    Betaxolol Hydrochloride, Usp

    U.S.A
    Compamed
    Not Confirmed
    arrow

    09

    Bifeprunox Mesylate Bulk Drug Substa...

    U.S.A
    Compamed
    Not Confirmed
    arrow

    10

    Bradykinin Acetate Npc-567

    U.S.A
    Compamed
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    CEP/COS

    read-more
    read-more

    01

    Clarithromycin

    CEP/COS

    The Pharmacy Technology
    Not Confirmed
    arrow

    02

    Dydrogesterone, Micronised

    CEP/COS

    The Pharmacy Technology
    Not Confirmed
    arrow

    03

    Lactulose, liquid, 634 g/l to 700 g/l

    CEP/COS

    The Pharmacy Technology
    Not Confirmed
    arrow

    04

    Lactulose, liquid, 667g/l

    CEP/COS

    The Pharmacy Technology
    Not Confirmed
    arrow

    05

    Terazosin hydrochloride dihydrate

    CEP/COS

    The Pharmacy Technology
    Not Confirmed
    arrow

    06

    Trandolapril

    CEP/COS

    The Pharmacy Technology
    Not Confirmed
    arrow

    07

    Trandolapril

    CEP/COS

    The Pharmacy Technology
    Not Confirmed
    arrow

    08

    Vancomycin hydrochloride

    CEP/COS

    The Pharmacy Technology
    Not Confirmed
    arrow

    09

    Verapamil hydrochloride

    CEP/COS

    The Pharmacy Technology
    Not Confirmed
    arrow
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Cadrenal and Abbott Collaborate on Novel Anticoagulant Tecarfarin for LVAD Patients

    Details:

    The collaboration aims to advance the novel anticoagulant ATI-5923 (tecarfarin), designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices.


    Lead Product(s): Tecarfarin

    Therapeutic Area: Hematology Brand Name: ATI-5923

    Study Phase: Phase IProduct Type: Small molecule

    Recipient: Cadrenal Therapeutics

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration August 06, 2024

    blank

    01

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tecarfarin

    Therapeutic Area : Hematology

    Highest Development Status : Phase I

    Recipient : Cadrenal Therapeutics

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Cadrenal and Abbott Collaborate on Novel Anticoagulant Tecarfarin for LVAD Patients

    Details : The collaboration aims to advance the novel anticoagulant ATI-5923 (tecarfarin), designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with implanted cardiac devices.

    Brand Name : ATI-5923

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    August 06, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries below the Knee

    Details:

    The FDA approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System to keep arteries open, delivering Everolimus to support healing in patients with chronic limb-threatening ischemia.


    Lead Product(s): Everolimus

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Esprit

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 29, 2024

    blank

    02

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Everolimus

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Abbott's Breakthrough Dissolving Stent Receives FDA Approval for Arteries below the Knee

    Details : The FDA approved the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System to keep arteries open, delivering Everolimus to support healing in patients with chronic limb-threatening ischemia.

    Brand Name : Esprit

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    April 29, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Abbott Broadens Access to Cutting-edge Biosimilars in Key Emerging Markets

    Details:

    Under the agreemeent, Abbott will commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa, and mAbxience will develop, manufacture and supply the biosimilar molecules.


    Lead Product(s): Undisclosed

    Therapeutic Area: Oncology Brand Name: Undisclosed

    Study Phase: UndisclosedProduct Type: Large molecule

    Recipient: Mabxience

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Agreement September 20, 2023

    blank

    03

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Undisclosed

    Therapeutic Area : Oncology

    Highest Development Status : Undisclosed

    Recipient : Mabxience

    Deal Size : Undisclosed

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Abbott Broadens Access to Cutting-edge Biosimilars in Key Emerging Markets

    Details : Under the agreemeent, Abbott will commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and Africa, and mAbxience will develop, manufacture and supply the biosimilar molecules.

    Brand Name : Undisclosed

    Molecule Type : Large molecule

    Upfront Cash : Undisclosed

    September 20, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon

    Details:

    Under the agreement, Abbott has exclusive worldwide commercialization rights for the SurVeil (paclitaxel) drug-coated balloon (DCB) for which Surmodics received FDA approval.


    Lead Product(s): Paclitaxel

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: SurVeil

    Study Phase: ApprovedProduct Type: Small molecule

    Recipient: Surmodics

    Deal Size: $92.0 million Upfront Cash: $25.0 million

    Deal Type: Agreement June 20, 2023

    blank

    04

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Paclitaxel

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved

    Recipient : Surmodics

    Deal Size : $92.0 million

    Deal Type : Agreement

    DEALS_DEV arrow-down

    Surmodics Receives FDA Approval for the SurVeil™ Drug-Coated Balloon

    Details : Under the agreement, Abbott has exclusive worldwide commercialization rights for the SurVeil (paclitaxel) drug-coated balloon (DCB) for which Surmodics received FDA approval.

    Brand Name : SurVeil

    Molecule Type : Small molecule

    Upfront Cash : $25.0 million

    June 20, 2023

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Abbott to Release Elecare® Amino Acid-Based Formulas to Help Meet Critical Patient Need

    Details:

    EleCare formulas are hypoallergenic and are used by infants and children who have severe food allergies or gastrointestinal (GI) disorders that require amino acid-based formulas.


    Lead Product(s): Amino Acid-Based Therapeutic

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Elecare

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable May 24, 2022

    blank

    05

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Amino Acid-Based Therapeutic

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Abbott to Release Elecare® Amino Acid-Based Formulas to Help Meet Critical Patient Need

    Details : EleCare formulas are hypoallergenic and are used by infants and children who have severe food allergies or gastrointestinal (GI) disorders that require amino acid-based formulas.

    Brand Name : Elecare

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    May 24, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Abbott Introduces Single-Dose Formulation of Carbetocin for Prevention of Postpartum Haemorrhage in India

    Details:

    The novel, room-temperature-stable (RTS), single-dose formulation of Carbetocin will address prevailing challenges with existing protocols that require cold-chain storage and transportation.


    Lead Product(s): Carbetocin Acetate

    Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Brand Name: Undisclosed

    Study Phase: ApprovedProduct Type: Peptide

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable August 31, 2021

    blank

    06

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Carbetocin Acetate

    Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Abbott Introduces Single-Dose Formulation of Carbetocin for Prevention of Postpartum Haemorrhage i...

    Details : The novel, room-temperature-stable (RTS), single-dose formulation of Carbetocin will address prevailing challenges with existing protocols that require cold-chain storage and transportation.

    Brand Name : Undisclosed

    Molecule Type : Peptide

    Upfront Cash : Not Applicable

    August 31, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Abbott Gets CDSCO Approval for Marketing of Estradiol, Dydrogesterone FDC

    Details:

    Estradiol, also spelled oestradiol, is an estrogen steroid hormone and the major female sex hormone. It is involved in the regulation of the estrous and menstrual female reproductive cycles.


    Lead Product(s): Estradiol,Dydrogesterone

    Therapeutic Area: Musculoskeletal Brand Name: Femoston

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 15, 2021

    blank

    07

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Estradiol,Dydrogesterone

    Therapeutic Area : Musculoskeletal

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Abbott Gets CDSCO Approval for Marketing of Estradiol, Dydrogesterone FDC

    Details : Estradiol, also spelled oestradiol, is an estrogen steroid hormone and the major female sex hormone. It is involved in the regulation of the estrous and menstrual female reproductive cycles.

    Brand Name : Femoston

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    July 15, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    AstraZeneca Pharma, Abbott Healthcare Terminate Distribution Agreements for Diabetes Drug in India

    Details:

    After termination of the agreement, AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names Forxiga, Xigduo and Qtern respectively.


    Lead Product(s): Dapagliflozin Propanediol Monohydrate,Metformin

    Therapeutic Area: Endocrinology Brand Name: Xigduo

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: AstraZeneca

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Termination May 28, 2021

    blank

    08

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Dapagliflozin Propanediol Monohydrate,Metformin

    Therapeutic Area : Endocrinology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : AstraZeneca

    Deal Size : Undisclosed

    Deal Type : Termination

    DEALS_DEV arrow-down

    AstraZeneca Pharma, Abbott Healthcare Terminate Distribution Agreements for Diabetes Drug in India

    Details : After termination of the agreement, AstraZeneca India will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names Forxiga, Xigduo and Qtern r...

    Brand Name : Xigduo

    Molecule Type : Small molecule

    Upfront Cash : Undisclosed

    May 28, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold

    Details:

    This is the first Investigational Device Exemption (IDE) trial in the U.S. to evaluate a fully resorbable device to treat blocked arteries below the knees, or critical limb ischemia (CLI), in people battling advanced stages of peripheral artery disease (PAD).


    Lead Product(s): Everolimus

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: ESPRIT BTK

    Study Phase: UndisclosedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 03, 2020

    blank

    09

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Everolimus

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Undisclosed

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Abbott Announces Start of Trial to Evaluate the New Esprit™ BTK Drug-Eluting Resorbable Scaffold

    Details : This is the first Investigational Device Exemption (IDE) trial in the U.S. to evaluate a fully resorbable device to treat blocked arteries below the knees, or critical limb ischemia (CLI), in people battling advanced stages of peripheral artery disease (...

    Brand Name : ESPRIT BTK

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 03, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Abbott’s Once-A-Day Ivabradine Receives DCGI Approval for Heart Failure and Angina patients

    Details:

    Approval marks the first once-a-day formulation for Ivabradine in India, which will help increase adherence to therapy for chronic heart failure and chronic stable angina.


    Lead Product(s): Ivabradine Hydrochloride

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 02, 2020

    blank

    10

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed

    Abbott Laboratories

    U.S.A
    arrow
    The Pharmacy Technology
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Ivabradine Hydrochloride

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Abbott’s Once-A-Day Ivabradine Receives DCGI Approval for Heart Failure and Angina patients

    Details : Approval marks the first once-a-day formulation for Ivabradine in India, which will help increase adherence to therapy for chronic heart failure and chronic stable angina.

    Brand Name : Undisclosed

    Molecule Type : Small molecule

    Upfront Cash : Not Applicable

    September 02, 2020

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Abbott Laboratories and get a quotation

    Abbott Laboratories is a supplier offers 115 products (APIs, Excipients or Intermediates).

    Find a price of Lactulose bulk with DMF, CEP, JDMF offered by Abbott Laboratories

    Find a price of Dydrogesterone bulk with CEP, JDMF offered by Abbott Laboratories

    Find a price of Verapamil Hydrochloride bulk with DMF, CEP offered by Abbott Laboratories

    Find a price of Chondroitin Sulfate Sodium bulk with DMF offered by Abbott Laboratories

    Find a price of Clarithromycin bulk with CEP offered by Abbott Laboratories

    Find a price of Lactulose bulk with CEP offered by Abbott Laboratories

    Find a price of Pancreatin bulk with DMF offered by Abbott Laboratories

    Find a price of Thyroid bulk with DMF offered by Abbott Laboratories

    Find a price of Trandolapril bulk with CEP offered by Abbott Laboratories

    Find a price of Zotarolimus bulk with DMF offered by Abbott Laboratories

    Find a price of 2-Thiouracil bulk offered by Abbott Laboratories

    Find a price of Amikacin Sulfate bulk offered by Abbott Laboratories

    Find a price of Amrinone bulk offered by Abbott Laboratories

    Find a price of Atracurium Besylate bulk offered by Abbott Laboratories

    Find a price of Betaxolol bulk offered by Abbott Laboratories

    Find a price of Bifeprunox bulk offered by Abbott Laboratories

    Find a price of Bradykinin bulk offered by Abbott Laboratories

    Find a price of Butabarbital bulk offered by Abbott Laboratories

    Find a price of Butorphanol Tartrate bulk offered by Abbott Laboratories

    Find a price of Carbidopa bulk offered by Abbott Laboratories

    Find a price of CAS 50-28-2 bulk offered by Abbott Laboratories

    Find a price of Clindamycin Hydrochloride bulk offered by Abbott Laboratories

    Find a price of Cytolex bulk offered by Abbott Laboratories

    Find a price of Dicumarol bulk offered by Abbott Laboratories

    Find a price of Diethylstilbestrol bulk offered by Abbott Laboratories

    Find a price of Dimethadione bulk offered by Abbott Laboratories

    Find a price of Divalproex Sodium bulk offered by Abbott Laboratories

    Find a price of Dobutamine Hydrochloride bulk offered by Abbott Laboratories

    Find a price of Enflurane bulk offered by Abbott Laboratories

    Find a price of Erythromycin bulk offered by Abbott Laboratories

    Find a price of Erythromycin Estolate bulk offered by Abbott Laboratories

    Find a price of Erythromycin Ethyl Succinate bulk offered by Abbott Laboratories

    Find a price of Erythromycin Stearate bulk offered by Abbott Laboratories

    Find a price of Erythromyclamine bulk offered by Abbott Laboratories

    Find a price of Ethchlorvynol bulk offered by Abbott Laboratories

    Find a price of Fentanyl bulk offered by Abbott Laboratories

    Find a price of Fentanyl Citrate bulk offered by Abbott Laboratories

    Find a price of Genesa bulk offered by Abbott Laboratories

    Find a price of Glipizide bulk offered by Abbott Laboratories

    Find a price of Gonadorelin Acetate bulk offered by Abbott Laboratories

    Find a price of Haloperidol bulk offered by Abbott Laboratories

    Find a price of Hydrochlorothiazide bulk offered by Abbott Laboratories

    Find a price of Hydroxychloroquine Sulphate bulk offered by Abbott Laboratories

    Find a price of Inositol bulk offered by Abbott Laboratories

    Find a price of Iopamidol bulk offered by Abbott Laboratories

    Find a price of Ketorolac Trometamol bulk offered by Abbott Laboratories

    Find a price of Lincomycin Hydrochloride bulk offered by Abbott Laboratories

    Find a price of Lovastatin bulk offered by Abbott Laboratories

    Find a price of MAPROTILINE HYDROCHLORIDE bulk offered by Abbott Laboratories

    Find a price of Meprobamate bulk offered by Abbott Laboratories

    Find a price of Methocarbamol bulk offered by Abbott Laboratories

    Find a price of Methyclothiazide bulk offered by Abbott Laboratories

    Find a price of Methylprednisolone Hemisuccinate bulk offered by Abbott Laboratories

    Find a price of Midazolam bulk offered by Abbott Laboratories

    Find a price of Oxtriphylline bulk offered by Abbott Laboratories

    Find a price of Oxybutynin Hydrochloride bulk offered by Abbott Laboratories

    Find a price of Paracetamol bulk offered by Abbott Laboratories

    Find a price of Pentamidine Isethionate bulk offered by Abbott Laboratories

    Find a price of Pentetic Acid bulk offered by Abbott Laboratories

    Find a price of Pentigide bulk offered by Abbott Laboratories

    Find a price of Prazosin Hydrochloride bulk offered by Abbott Laboratories

    Find a price of Propofol bulk offered by Abbott Laboratories

    Find a price of Propoxyphene Napsylate bulk offered by Abbott Laboratories

    Find a price of Selenium Sulfide bulk offered by Abbott Laboratories

    Find a price of Simethicone bulk offered by Abbott Laboratories

    Find a price of Sirolimus bulk offered by Abbott Laboratories

    Find a price of Sodium Arsanilate bulk offered by Abbott Laboratories

    Find a price of Spectinomycin bulk offered by Abbott Laboratories

    Find a price of Spectinomycin Dihydrochloride Pentahydrate bulk offered by Abbott Laboratories

    Find a price of Succinylcholine Chloride bulk offered by Abbott Laboratories

    Find a price of Sulfiram bulk offered by Abbott Laboratories

    Find a price of Terazosin HCl bulk offered by Abbott Laboratories

    Find a price of Tetracycline bulk offered by Abbott Laboratories

    Find a price of Thiamylal bulk offered by Abbott Laboratories

    Find a price of Thyrotropin-Releasing Hormone bulk offered by Abbott Laboratories

    Find a price of Tromethamine API bulk offered by Abbott Laboratories

    Find a price of Tubocurarine Chloride bulk offered by Abbott Laboratories

    Find a price of Vancomycin Hydrochloride bulk offered by Abbott Laboratories

    Find a price of Verapamil bulk offered by Abbott Laboratories

    Find a price of Vitamin K1 bulk offered by Abbott Laboratories

    Find a price of CURRICULUM VITAE OF ABBOTT'S THERAPEUTIC COMMITTEE bulk offered by Abbott Laboratories

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN NORTH CHICAGO, ILLINOIS. bulk offered by Abbott Laboratories

    Find a price of DEXOXYEPHEDRINE HCL bulk offered by Abbott Laboratories

    Find a price of SPEC, STANDARD CONTROL PROCEDS & TEXT METHODS FOR INACTIVE INGREDS. bulk offered by Abbott Laboratories

    Find a price of METHAPYRILENE HCL bulk offered by Abbott Laboratories

    Find a price of STANDARD TEST METHODS FOR TESTING SVP & LVP PRODUCTS (5-1-80 - 5-1-81) bulk offered by Abbott Laboratories

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN ROCKY MOUNT, NORTH CAROLINA. bulk offered by Abbott Laboratories

    Find a price of NIKKOMYCIN Z HYDROCHLORIDE bulk offered by Abbott Laboratories

    Find a price of FACILITIES bulk offered by Abbott Laboratories

    Find a price of FACILITIES AND OPERATING PROCEDURES IN LATINA, ITALY (LABORATORI ABBOTT S.P.A.) bulk offered by Abbott Laboratories

    Find a price of RENAL KETO ACID PRODUCT bulk offered by Abbott Laboratories

    Find a price of FACILITIES LOCATED IN QUEENBOROUGH, KENT, UK bulk offered by Abbott Laboratories

    Find a price of 2-(2-FORMYLHYDRAZINO)-4-(5-NITRO-2-FURYL)-THIAZOLE (AS-L7665)&A-2L203 bulk offered by Abbott Laboratories

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN MCPHERSON, KANSAS. bulk offered by Abbott Laboratories

    Find a price of FACILS, PERSONNEL & GEN OPER PROCEDS FOR THE MURINE CO. FACILS. bulk offered by Abbott Laboratories

    Find a price of I-125-FIBRINOGEN (HUMAN) SENSOR bulk offered by Abbott Laboratories

    Find a price of STD CONTROL PROCEDURES,RAW DRUG CODES FOR SVP & LVP PRODUCTS,5-80 5-81 bulk offered by Abbott Laboratories

    Find a price of MFGR PROCEDS,CTRLS,FACILS & PACKAGING P.RICO PLANT bulk offered by Abbott Laboratories

    Find a price of STD TEST METHODS FOR TESTING SVP & LVP PRODUCTS(PERIOD 5-1-80 - 5-1-81 bulk offered by Abbott Laboratories

    Find a price of MANUF, PACKAGING AND LABELING OF BULK CALCIUM AND SODIUM CYCLAMATE bulk offered by Abbott Laboratories

    Find a price of MANUFACTURING SITE,FACILITES,PERSONNEL, AND GENERAL MANUFACTURING PROCEDURES. bulk offered by Abbott Laboratories

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN ETHRANE IN QUEENBOUROUGH, KENT, ENGLAND. bulk offered by Abbott Laboratories

    Find a price of IRON-58 STERILE SOLUTION bulk offered by Abbott Laboratories

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN QUEENBOURGH, KENT, UNITED KINGDOM. bulk offered by Abbott Laboratories

    Find a price of M-259 (NSC 51954) bulk offered by Abbott Laboratories

    Find a price of LIFE CARE FLEXIBLE CONTAINERS bulk offered by Abbott Laboratories

    Find a price of QUALITY ASSURANCE OPERATIONS STANDARDS bulk offered by Abbott Laboratories

    Find a price of QUALITY ASSURANCE OPERATION STANDARDS bulk offered by Abbott Laboratories

    Find a price of STD.CONTROL PROCEDURES,RAW DRUG CODES FOR SVP & LVP PRODUCTS(5-80 5-81 bulk offered by Abbott Laboratories

    Find a price of ABBOTT LABS QUALITY ASSURANCE OPERATIONS STANDARDS MANUAL PHARM. DIV. bulk offered by Abbott Laboratories

    Find a price of FACILS., PROCEDS., & CONTROLS-AT THE BARCELONETA, PUERTO RICO PLANT bulk offered by Abbott Laboratories

    Find a price of CYCLAMATE, SACCHARIN AND CYCLOHEXYLAMINE bulk offered by Abbott Laboratories

    Find a price of SEMI-WORKS AREA IN QUEENBOROUGH, KENT, UNITED KINGDOM bulk offered by Abbott Laboratories

    Find a price of FACILITIES AND OPERATING PROCEDURES IN QUEENBOROUGH, ENGLAND bulk offered by Abbott Laboratories

    Find a price of ANTIBIOTIC M-188 (MACROLIDE ANTIBIOTIC OF THE ERYTHROMYCIN GROUP) bulk offered by Abbott Laboratories

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search